Osteoarthritis Therapeutics : Personalized Medicine For Osteoarthritis
  • Published On: 30-03-2022

Osteoarthritis Therapeutics : Personalized Medicine For Osteoarthritis

Remarkable advances have been made in diagnosing, treating, and monitoring disease activity in patients with osteoarthritis, including the conceptualization of personalized OA medications. Essential features of biomarkers that will have clinical relevance for a personalized approach to therapy for RA include the ease of measurement, acceptable levels of sensitivity and specificity, and test methods that are accessible and interpretable by clinicians. 

 

The use of biomarkers to identify patients who are likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposure to therapies that are unlikely to be effective or expose patients to serious treatment-related side-effects. The combination of unique biomarkers and baseline clinical characteristics such as sex and age may further enhance efforts to personalize treatment regimens for RA.  

 

π†πžπ­ 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐒𝐠𝐑𝐭𝐬, π†π«πšπ› 𝐏𝐃𝐅 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994 

 

COVID -19 Impact on the Osteoarthritis Therapeutics Market 

The market for osteoarthritis therapeutics is anticipated to be marginally affected due to the outbreak of COVID-19. Among drug types, the use of corticosteroids has reduced. Although there is no evidence to suggest that corticosteroid injections lead to a substantial increase in the risk of infection, there is a possible reduction in the immune response for up to a few weeks following the procedure. While this risk is extremely low, it needs to be considered when deciding to proceed with the procedure.

 

It should also be noted that the WHO, in one of its guidelines for the management of severe acute respiratory infection in patients with coronavirus, suggested avoiding systemic corticosteroids.  

 

The adoption of pain medications for the management of pain associated with osteoarthritis is expected to remain high over the coming decade, which is anticipated to propel the growth of the market during the study period. 

 

OTC and prescription NSAIDs are widely used to relieve pain in osteoarthritis patients. As per a study published by the National Center for Biotechnology Information in 2019, more than 50% of osteoarthritis patients in the US are prescribed NSAIDs. Similarly, in Europe, of the total number of osteoarthritis patients using prescription medications (47%), 60% received NSAIDs. 

 

The visco supplementation agents segment accounted for the largest share of the osteoarthritis therapeutics market in 2019. The rising incidence of knee osteoarthritis is the major factor driving the growth of this segment. Visco supplementation effectively eases the pain of osteoarthritis through injections that fill up the joint’s synovial fluid, thus offering better lubrication of the joints. 

 

The major players operating in osteoarthritis therapeutics market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US).